IRADIMED (IRMD), a US based maker of MRI compatible medical devices, has drawn investor attention recently as its shares show mixed short term moves but a much stronger picture over the past year.

At a share price of US$98.95, IRADIMED has seen a 1 day share price return of 1.23% decline and a 7 day share price return of 5.13% decline, yet its 1 year total shareholder return of 91.95% and 5 year total shareholder return of 346.3% point to strong longer term momentum that recent volatility has not erased.

If IRADIMED's strong long term total shareholder returns have you curious about other healthcare names, take a look at our screener of 32 healthcare AI stocks as a starting point for fresh ideas.

So with IRADIMED posting strong multi year total returns, solid recent revenue and net income figures, and a share price below the US$120 analyst target, is there still value on the table, or is the market already pricing in future growth?

Most Popular Narrative: 17.5% Undervalued

With IRADIMED's fair value estimate at US$120 versus the recent close near US$98.95, the most followed narrative sees more support under the current price than the market is offering.

The pricing power associated with the new 3870 pump (management expects a ~12% higher average selling price than the older model) should directly support higher gross margins, while the company's demonstrated ability to maintain ~78% gross margin yields operating leverage, boosting both net margins and earnings per share as the business scales.

Want to see what is baked into that US$120 fair value? The narrative leans heavily on steady revenue expansion, resilient margins, and a richer earnings multiple. Curious how those pieces fit together into one pricing story? The full narrative lays out the assumptions line by line.

Result: Fair Value of US$120 (UNDERVALUED)

However, this story can change quickly if the narrow product lineup or any supply chain hiccups slow pump shipments, which could pressure both revenue and margin assumptions.

Another View: Rich P/E Puts Pressure On The Story

That 17.5% gap to the US$120 fair value sounds appealing, but the current P/E of 56.3x is very high compared with the US Medical Equipment industry at 27.7x and a fair ratio of 20.6x. If sentiment cools, the share price could move closer to those lower anchors.

Next Steps

If this mix of optimism and concern around IRADIMED leaves you unsure, take a closer look at the underlying data now and weigh both sides for yourself, starting with 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If IRADIMED has sharpened your focus, do not stop here. Use this momentum to check fresh ideas so you are not leaving potential opportunities untouched.

• Zero in on quality at a discount by scanning our list of 48 high quality undervalued stocks that pair fundamentals with appealing price tags.
• Strengthen your income stream by reviewing 14 dividend fortresses that aim to combine yield with resilience.
• Prioritize resilience by focusing on 68 resilient stocks with low risk scores that score well on stability and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.